Analyzing Childhood Recall Antigens in Patients With Pancreatic CancerAlbert Einstein College of Medicine / Pancreatic Cancer Action Network (PCAN)
ClinicalTrials.gov Identifier: NCT03848182
Investigators at Albert Einstein College of Medicine, in collaboration with the Pancreatic Cancer Action Network (PCAN), have opened a Phase II clinical trial of gemcitabine with tetanus toxoid vaccine booster for patients with pancreatic cancer. Patients diagnosed with pancreatic ductal carcinoma will be treated with gemcitabine as standard of care and boosted once with the human childhood vaccine to tetanus toxoid.
From the study summary:
“The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as ‘T cells with tumor killing capacity’, are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses.) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are planned in future clinical trials). The goal of this study is to test whether one TT vaccination combined with Gemcitabine treatment activates the same T cells in pancreatic cancer patients.”
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to email@example.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.